Inhibrx Biosciences (INBX) EBT Margin (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly EBT Margin of 2204.0% for Q2 2025, down 186021700.0% year-over-year from N/an in Q2 2024, and up 95.4% quarter-over-quarter from 47865.0% in Q4 2024.
Powered by 
Analysis
Inhibrx Biosciences (INBX) EBT Margin (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported EBT Margin for 3 consecutive years, with 2204.0% the latest figure, recorded in Q2 2025.
- In Q2 2025, EBT Margin fell 186021700.0% year-over-year to 2204.0%; the TTM figure through Dec 2025 stood at 10003.79% (down 10201982.0% YoY), while the FY2025 annual figure was 10773.31%, down 85456031.0% from the prior year.
- EBT Margin improved to 2204.0% in Q2 2025 per INBX's latest filing, from 47865.0% in the prior quarter.
- Across five years, EBT Margin topped out at 1858013.0% in Q2 2024 and bottomed at 156823.33% in Q2 2023.
- Historically, EBT Margin has averaged 266995.57% across 3 years, with a median of 24573.63% in 2023.
- Annual changes were most pronounced in 2024 — EBT Margin jumped 201483633 bps — and 2025, when it sank 186021700 bps.
- Inhibrx Biosciences' EBT Margin stood at 5628.76% in 2023, then sank by 750 bps to 47865.0% in 2024, then soared by 95 bps to 2204.0% in 2025.
- Business Quant data shows INBX's EBT Margin at 2204.0% in Q2 2025, 47865.0% in Q4 2024, and 1858013.0% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -2,204.00% |
| Dec 31, 2024 | -47,865.00% |
| Jun 30, 2024 | 1,858,013.00% |
| Dec 31, 2023 | -5,628.76% |
| Sep 30, 2023 | -43,518.49% |
| Jun 30, 2023 | -156,823.33% |